Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to ...

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with ...

Participants who are enrolled will be given a dose of ADI-001, followed by a 28-day dose-limiting toxicity window.

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.